ISRCTN97515110 https://doi.org/10.1186/ISRCTN97515110

Investigating whether topical application of a non toxic molecule improves epidermal pH and barrier function in atopic dermatitis

Submission date	Recruitment status	[ ] Prospectively registered
21/10/2010	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
21/10/2010	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
30/09/2016	Skin and Connective Tissue Diseases	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Neil Gibbs

Contact details
Dermatological Sciences
Stopford Building
Oxford Road
Manchester
United Kingdom
M13 9PT
-
neil.gibbs@manchester.ac.uk

Additional identifiers

Protocol serial number
7064

Study information

Scientific Title

Investigating whether topical application of a non toxic molecule improves epidermal pH and barrier function in atopic dermatitis

Study objectives
It is understood that the skin of people with atopic dermatitis (AD) does not act as an efficient barrier against chemicals and microbes that can enter the skin. One of the chemicals in the skin that may be important in barrier function is called Filaggrin. This study examines whether application of a naturally-occuring molecule onto the skin of people with AD may improve the barrier function of their skin.

Ethics approval required
Old ethics approval format

Ethics approval(s)
MREC, ref: 08/H1009/51

Study design
Single-centre randomised interventional trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Topic: Skin; Subtopic: Skin (all Subtopics); Disease: Dermatology

Interventions
1. Intervention: Gel containing a naturally-occuring chemical onto the skin of one their forearms every day for 6 weeks
2. Control: On the other forearm they will be asked to apply the same cream/gel that doesn't contain any of the naturally-occuring molecule

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Filaggrin

Primary outcome(s)
Each week volunteers will be asked to complete a short questionnaire (POEM)

Key secondary outcome(s))
1. General skin condition using a well established scoring system for AD (SCORAD)
2. Skin barrier function transepidermal water loss (TEWL), measured at monthly intervals

Completion date

01/01/2011

Eligibility

Key inclusion criteria
Not provided at time of registration

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/09/2008

Date of final enrolment
01/01/2011

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
The University of Manchester
Manchester
United Kingdom
M13 9PT

Sponsor information

Organisation
Biotechnology and Biological Science Research Council (BBSRC) (UK)

ROR
https://ror.org/00cwqg982

Funder(s)

Funder type
Research council

Funder Name
Biotechnology and Biological Sciences Research Council

Alternative Name(s)
UKRI - Biotechnology And Biological Sciences Research Council, Agricultural and Food Research Council, Biotechnology & Biological Sciences Research Council, BBSRC, BBSRC UK, AFRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary